Acasti Competitors

Delisted . USA . 
Stock . Acasti Pharma
ACSTDelisted Stock  USD 3.37  0.01  0.30%   
Acasti Pharma competes with Tonix Pharmaceuticals, Jaguar Animal, Ibio, Akari Therapeutics, and Aditxt; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Acasti Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Acasti Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Acasti Pharma competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acasti Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.163.208.16
Details
Intrinsic
Valuation
LowRealHigh
0.132.617.57
Details
Naive
Forecast
LowNextHigh
0.073.288.24
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.353.383.41
Details

Acasti Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Acasti Pharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Acasti and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Acasti Pharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ADTX
+ 0.83
AKTX
AKTX
+ 0.75
DFFN
ADTX
+ 0.7
DFFN
ADTX
+ 0.68
TNXP
DFFN
+ 0.63
JAGX
ABVC
+ 0.62
DFFN
  
High negative correlations   
ADTX
- 0.74
IBIO
AKTX
- 0.66
IBIO
PULM
- 0.59
AKTX
AKTX
- 0.56
ARDS
ABVC
- 0.51
ARDS
IBIO
- 0.5
DFFN

Risk-Adjusted Indicators

There is a big difference between Acasti Stock performing well and Acasti Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Acasti Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TNXP  5.73 (0.92) 0.00 (0.14) 0.00 
 0.00 
 14.29 
(13.33)
 34.91 
JAGX  2.91 (0.25) 0.00 (0.24) 0.00 
 0.00 
 8.13 
(7.94)
 27.65 
DFFN  2.40 (0.43) 0.00  0.76  0.00 
 0.00 
 4.09 
(5.32)
 12.34 
IBIO  3.75  0.46  0.10  0.89  3.57 
(4.95)
 7.76 
(6.47)
 30.48 
ARDS  7.73  1.21  0.10 (14.28) 7.66 
(12.31)
 12.50 
(12.50)
 140.53 
AKTX  4.11 (1.38) 0.00 (20.95) 0.00 
 0.00 
 4.84 
(12.30)
 47.27 
ADTX  7.46 (6.35) 0.00 (19.26) 0.00 
 0.00 
 6.04 
(28.15)
 50.07 
ABVC  3.68 (0.18) 0.00  0.47  0.00 
 0.00 
 7.25 
(9.09)
 35.84 
PULM  5.30  2.23  0.45 (4.08) 3.26 
(7.11)
 12.29 
(4.76)
 92.85 
ONTX  4.73  1.01  0.15 (0.59) 4.35 
(5.89)
 7.69 
(8.33)
 66.73 
All Fundamental Data

Acasti Pharma Competitive Analysis

The better you understand Acasti Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Acasti Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Acasti Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ACST TNXP JAGX DFFN IBIO ARDS AKTX ADTX ABVC PULM
 0.30 
 3.37 
Acasti
 5.00 
 0.19 
Tonix
 5.05 
 1.04 
Jaguar
 5.48 
 3.27 
Diffusion
 7.76 
 2.64 
Ibio
 8.00 
 0.27 
Aridis
 4.84 
 1.30 
Akari
 6.25 
 0.34 
Aditxt
 3.51 
 0.55 
ABVC
 0.16 
 6.12 
Pulmatrix
Market Volatility
(90 Days Market Risk)
Very risky
Dangerous
Very risky
Very steady
Dangerous
Very steady
Slightly risky
Slightly risky
Abnormally volatile
Very risky
Market Performance
(90 Days Performance)
Good
Very Weak
Very Weak
Very Weak
OK
Very Weak
Very Weak
Very Weak
Very Weak
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
High
Dangerous
Quite High
Dangerous
Very High
Very High
Very High
Quite High
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Buy
Hold
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Strong Hold
Not Rated
Hold
Not Rated
Hold
Hold
Hold
Strong Sell
Current Ratio
11.13
12.05
1.02
11.59
1.48
0.41
3.73
0.52
2.68
8.19
Net Asset
73.3 M
154.46 M
50.76 M
22.64 M
28.73 M
14.7 M
4.36 M
44.58 M
14.49 M
33.96 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.95
EBITDA
(11.3 M)
(114.09 M)
(33.13 M)
(15.97 M)
(14.02 M)
(29.51 M)
(16.8 M)
(25.46 M)
(8.13 M)
(12.65 M)
Current Valuation
11.17 M
15.97 M
33.27 M
(6.02 M)
17.35 M
12.11 M
30.94 M
14.61 M
8.85 M
11.57 M
Price To Book
0.58
0.48
0.9
0.51
1.36
5.4
3.07
0.6
0.81
2.05
Operating Margin
N/A
-8.31
-2.64
N/A
-19.48
-9.58
N/A
-134.97
-8.34
-3.8
Retained Earnings
(211.12 M)
(600.66 M)
(308.25 M)
(145.6 M)
(313.85 M)
(195.67 M)
(227.46 M)
(127.74 M)
(65.42 M)
(287.6 M)
Current Asset
11.33 M
46.36 M
8.45 M
3.29 M
23.91 M
27.39 M
69.66 M
N/A
N/A
8.34 M
Beta
1.52
2.08
0.88
1.76
-3.37
0.78
0.95
1.08
0.82
0.99
Number Of Employees
9
103
49
13
16
37
6
47
16
22
Shares Outstanding
10.14 M
186.89 M
11.8 M
2.04 M
9.14 M
36.21 M
20.65 M
14.23 M
12.24 M
3.65 M
Cash Flow From Operations
(12.33 M)
(102 M)
(33.24 M)
(14.97 M)
(18.55 M)
(29.13 M)
(16.43 M)
(18.58 M)
(4.24 M)
(15.98 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
11.56 M
9.81 M
37.09 M
67.89 K
4.46 M
6.13 M
4.58 M
18.22 M
2.28 M
8.76 M
Return On Equity
-0.19
-1.63
-2.91
-0.64
-0.84
N/A
-12.81
-34.94
-3.2
-0.59
Z Score
N/A
N/A
N/A
69.08
N/A
-26.03
N/A
N/A
N/A
N/A
Return On Asset
-0.12
-0.52
-0.35
-0.38
-0.3
-1.08
-1.73
-1.18
-0.45
-0.3
Number Of Shares Shorted
154.19 K
7.67 M
332.32 K
2.54 K
307.8 K
2 M
21.29 K
910.84 K
186.19 K
7.05 K
Book Value Per Share
5.86
57.61
4.06
6.97
2.47
-0.77
-0.035
486.96
1.06
4.93
Current Liabilities
1.14 M
6.65 M
3.91 M
3.68 M
2.29 M
3.06 M
21.12 M
N/A
N/A
4.11 M
Total Asset
73.3 M
154.46 M
50.76 M
22.64 M
28.73 M
14.7 M
4.36 M
44.58 M
14.49 M
33.96 M
Debt To Equity
0.007
0.003
N/A
0.001
0.44
-0.18
0.07
3.21
0.34
0.044
Short Ratio
3.84
0.35
1.12
0.29
1.46
0.22
1.92
0.16
0.7
0.75
Target Price
7.97
21.0
6.0
40.0
4.3
10.0
80.0
61.0
2.02
10.0
Shares Owned By Institutions
21.22
0.23
1.95
10.27
31.92
11.6
0.5
0.25
3.01
7.16
Market Capitalization
36.5 M
35.51 M
12.27 M
8.98 M
23.3 M
13.24 M
30.35 M
4.82 M
6.72 M
22.35 M
Price To Earning
15.34
-0.69
-0.96
-0.6
-2.18
-1.41
-2.15
N/A
N/A
-1.3
Price To Earnings To Growth
N/A
N/A
-0.02
N/A
N/A
-0.02
N/A
N/A
N/A
N/A
Price To Sales
208.39
2.85
1.2
N/A
138.03
7.33
N/A
14.63
49.27
1.96
Net Income
(12.85 M)
(116.66 M)
(41.3 M)
(15.59 M)
(24.91 M)
(30.37 M)
(10.01 M)
(32.38 M)
(10.52 M)
(14.12 M)
Earnings Per Share
-1.43
-80.39
20.2
-7.11
-4.03
-1.15
-2.58
-22893.75
-0.81
-2.64
Shares Owned By Insiders
38.39
0.16
12.02
0.23
0.14
31.53
11.9
0.01
22.92
N/A
Revenue
N/A
7.77 M
9.76 M
N/A
225 K
N/A
N/A
645.18 K
152.43 K
7.3 M
Working Capital
22.33 M
28.88 M
(8.02 M)
20.22 M
11.83 M
(25.27 M)
1.77 M
(18.98 M)
(4.28 M)
16.93 M
Cash And Equivalents
38.39 M
145.48 M
9.01 M
25.86 M
33.52 M
6.32 M
8.15 M
803.97 K
2.99 M
42.91 M
Cash Per Share
0.86
3.38
0.08
12.68
3.72
0.36
0.14
0.71
0.09
12.67
Gross Profit
120 K
N/A
2 M
N/A
2.17 M
(22.61 M)
N/A
166.94 K
350.71 K
6.07 M
Day Typical Price
3.34
0.2
1.02
3.22
2.63
0.26
1.24
0.33
0.55
6.22
Accumulation Distribution
0.0725
0.0952
0.0857
0.0549
0.14
0.33
0.17
0.0588
0.0702
0.0942
Market Facilitation Index
0.25
0.02
0.09
0.18
0.39
0.1
0.23
0.02
0.04
0.62
Daily Balance Of Power
(0.04)
(0.50)
0.5556
0.9444
0.4872
0.2
0.2609
1.0
(0.50)
0.0161
Period Momentum Indicator
(0.01)
(0.01)
0.05
0.17
0.19
0.02
0.06
0.02
(0.02)
0.01
Rate Of Daily Change
1.0
0.95
1.05
1.05
1.08
1.08
1.05
1.06
0.96
1.0
Day Median Price
3.33
0.2
1.0
3.19
2.63
0.25
1.22
0.33
0.55
6.27
Price Action Indicator
0.04
(0.01)
0.06
0.17
0.11
0.03
0.12
0.02
(0.01)
(0.15)
Relative Strength Index
87.05
50.98
7.48
22.85
53.92
58.8
72.9
23.08
76.13
47.21
Coefficient Of Variation
1233.46
(1,721)
(2,931)
(595.23)
949.24
1318.41
(462.77)
(160.15)
(2,461)
532.31
Mean Deviation
3.0
5.73
2.91
2.4
3.75
7.73
4.11
7.46
3.68
5.3
Jensen Alpha
0.2957
(0.92)
(0.25)
(0.43)
0.4553
1.21
(1.38)
(6.35)
(0.18)
2.23
Total Risk Alpha
(0.34)
(1.81)
(0.88)
(0.99)
(0.28)
(1.32)
(2.36)
(7.90)
(1.14)
0.3417
Sortino Ratio
0.0722
N/A
N/A
N/A
0.1007
0.1035
N/A
N/A
N/A
0.4505
Downside Variance
9.63
N/A
N/A
N/A
16.3
109.52
N/A
N/A
N/A
20.59
Standard Deviation
4.38
8.37
4.55
3.0
5.1
16.01
6.29
10.09
5.73
11.58
Kurtosis
5.54
1.71
4.36
(0.33)
3.22
34.01
7.9
1.55
7.53
24.18
Potential Upside
9.42
14.29
8.13
4.09
7.76
12.5
4.84
6.04
7.25
12.29
Treynor Ratio
0.8462
(0.14)
(0.24)
0.759
0.8853
(14.28)
(20.95)
(19.26)
0.4698
(4.08)
Maximum Drawdown
25.09
34.91
27.65
12.34
30.48
140.53
47.27
50.07
35.84
92.85
Variance
19.16
69.97
20.66
8.98
26.01
256.26
39.6
101.84
32.79
134.05
Market Risk Adjusted Performance
0.8562
(0.13)
(0.23)
0.769
0.8953
(14.27)
(20.94)
(19.25)
0.4798
(4.07)
Risk Adjusted Performance
0.0704
(0.04)
(0.02)
(0.12)
0.0893
0.0677
(0.16)
(0.47)
(0.02)
0.1534
Skewness
1.76
0.2201
1.22
(0.24)
1.16
4.94
(1.71)
(1.21)
1.76
4.42
Semi Deviation
2.83
N/A
N/A
N/A
3.57
7.66
N/A
N/A
N/A
3.26
Information Ratio
0.0512
(0.07)
(0.06)
(0.21)
0.0797
0.0677
(0.24)
(0.64)
(0.06)
0.1766
Value At Risk
(3.85)
(13.33)
(7.94)
(5.32)
(6.47)
(12.50)
(12.30)
(28.15)
(9.09)
(4.76)
Expected Short fall
(3.77)
N/A
N/A
N/A
(4.95)
(12.31)
N/A
N/A
N/A
(7.11)
Downside Deviation
3.1
N/A
N/A
N/A
4.04
10.47
N/A
N/A
N/A
4.54
Semi Variance
8.01
N/A
N/A
N/A
12.75
58.73
N/A
N/A
N/A
10.6

Acasti Pharma Competition Performance Charts

Five steps to successful analysis of Acasti Pharma Competition

Acasti Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Acasti Pharma in relation to its competition. Acasti Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Acasti Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Acasti Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Acasti Pharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Acasti Pharma position

In addition to having Acasti Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USD Crypto Fund Thematic Idea Now

USD Crypto Fund
USD Crypto Fund Theme
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in Acasti Stock

If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY